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Background: Invasive fungal infection (IFI) is one of the most common nosocomial
infections. However, data on the epidemiology of IFI and susceptibility to antifungal
agents in China are quite limited, and in particular, no current data exist on the
microbiological, and clinical characteristics of IFI patients in Northeast China.
Objectives: The purpose of this study was to provide a retrospective review of the
clinical characteristics, laboratory test results, and risk factor predictions of inpatients
diagnosedwith IFI. Multivariate regression analysis was used to assess prognostic factors
associated with the mortality of these patients.
Methods: We retrospectively analyzed the results from 509 patients with IFI extracted
from the First Hospital of China Medical University from January 2013 to January 2018.
Results: Neutrophil numbers, total bilirubin, length of stay in the ICU, renal failure, use
of immunosuppressants within the past 30 days, stomach tube placement and septic
shock were risk factors for death from IFI. Recent surgery (within 2 weeks) and drainage
tube placement did not increase mortality in these IFI patients. Increased serum levels
of PCT (AUC 0.601, 95% CI 0.536–0.665, P = 0.003) and CRP (AUC 0.578, 95% CI
0.512–0.644, P = 0.020) provided effective predictors of 30-day mortality rates.
Conclusions: We report for the first time epidemiological data on invasive fungal
infections in Northeast China over the past 5 years. Despite the limited available clinical
data, these findings will greatly aid clinical health care workers with regard to the
identification, prevention, and treatment of IFI in hospitalized patients.
Keywords: invasive fungal infection, bacteremia, epidemic, single center, China
INTRODUCTION
Invasive fungal infection (IFI) is one of the most common nosocomial bloodstream
infections (Bassetti et al., 2016; Bosch et al., 2016) and may result in invasive
diseases in patients with various underlying diseases or other host factors. Invasive
diseases most frequently occur in bloodstream infections (mycosis) or via secondary
transmission to areas, such as the eyes, liver, spleen, bone, heart valves, and central
nervous system, or deep candidiasis (Pfaller and Diekema, 2007; Arendrup, 2010).
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In recent years, the incidence of IFI has been increasing,
especially within hospitalized patients (Fishman, 2007).
The pathogens responsible for IFI are mostly opportunistic
pathogens, including Candida, Aspergillus, and Cryptococcus
(Falagas et al., 2010). Among these, Candida albicans is the
most common (Fu et al., 2017). Increased incidence of IFI in
hospitals is associated with increased susceptibility to IFI in
immunocompromised patients, especially in patients with AIDS,
hematological diseases, malignant tumors, organ transplantation
or burns (Villarroel et al., 2010; Singh et al., 2016). Invasive
fungi can affect various tissues and systems throughout the
body, among which respiratory infections are the most common
(Singh and Husain, 2003). IFI in hospitals is often a coinfection
in some critically ill patients, and the basis of diagnosis must
be fungal culture and pathological examination, which take
a long time and are not conducive to early diagnosis and
treatment (Clancy and Nguyen, 2013; Kim et al., 2013). As
a result, there exists a high fatality rate in these IFI patients,
which has attracted increasing attention within the medical
community. Due to the limited number of studies, many
aspects of IFI remain poorly understood, including clinical
characteristics and prognostic factors. Most research on IFI
has been conducted in the United States and Europe, while
no reports on this condition exist from Northeast China. In
particular, microbiological and clinical data among Chinese
IFI patients are extremely scarce. There are no epidemiological
data on IFI associated with bacterial infections in hospitals
worldwide. In this study, we performed a retrospective review
as a means to partially elucidate the microbiological and
clinical characteristics of IFI patients in Northeast China, as
well as to aid in the prognosis and identify related risk factors
associated with this condition. Specifically, the goals of this
study were to (1) record the fungal species distribution and drug
resistance of blood- and sterile body fluid-isolated strains as an
approach to describe the clinical features of IFI, (2) describe
the clinical features of IFI in patients with bacterial infections,
and (3) determine the risk factors associated with mortality and
prognostic factors.
MATERIALS AND METHODS
Patient Selection
Data for this study were obtained from the electronic
medical record system, as extracted from the First Hospital
of China Medical University over the period from January
2013 to January 2018. Clinical data from hospitalized
patients with a diagnosis of IFI based on the presence
of an effective fungal specimen in culture were used in
this study. Information collected and recorded from these
patients included age, sex, length of hospital stay, antibiotic
application, chemotherapy, surgery, basic diseases, intensive
care unit (ICU) admission, mortality and any other relevant
clinical information. The patients at this hospital represent
those from the entire northeastern section of China, which
comprises a location where epidemic levels of IFI are believed
to exist.
Criteria for Study Inclusion
We collected all Candida, Cryptococcus, and other yeast isolates
recovered from blood; other sterile body fluids, including ascitic
fluid, and peritoneal dialysate fluid, pus, and tissue from patients
with invasive yeast infections for inclusion in this study (2008
version of EORTC/MSG criteria). The data collected included the
subject’s characteristics at baseline, haematologic diagnosis and
chemotherapy, risk factors for IFI, clinical features of IFI, fungal
test results, antifungal prophylaxis and treatment, and survival
status at discharge. The management of the patients receiving
antifungal prophylaxis and/or therapy was recorded, including
the date and nature of the change in treatment and survival status
at discharge. Each inpatient hospitalization represented one case,
and if a patient was re-hospitalized and received another round
of treatment, he/she was also considered a new and separate case.
Microbiological Test
Aseptic humoral samples (8–10ml) were collected and cultured
for 5 days. Positive samples were transferred to blood AGAR
plates and then bacterial isolates and fungal isolates passed at
35◦C for 48–72 h. Gram staining and microscopic examination
were performed simultaneously. Strain identification (bacterial
isolates and fungal isolates) was performed on a VITEK
2 Compact (Bio-Merieux SA, Marcy l ’etoile, France), and
susceptibility tests were performed with use of ATB FUNGUS 3
(Bio-Merieux SA, Marcy l ’etoile, France).
The drug susceptibility tests were performed with use of
ATB FUNGUS 3 (Bio-Merieux SA, Marcy l ’etoile, France).
Drug susceptibility tests consisted of application of ATB Fungus
3 yeast-like fungi into a drug susceptibility test box in strict
accordance with the “national clinical test operating procedures”
and reagent instructions for the procedure. The minimum
inhibitory concentration (MIC) value was determined according
to the CLSI m27-a3 and m27-s4 antifungal susceptibility test
standards. The quality control strains were Candida ATCC6258
and Candida albicans ATCC90028.
Definition and Abbreviations
IFI, invasive fungal infection; ICU, intensive care unit; SDD,
susceptible-dose dependent; PCT, procalcitonin; CRP, C-reactive
protein; BDG, 1–3-β-D-glucan.
Prolonged hospitalization was defined as a hospital stay longer
than 10 days.
Statistical Analysis
The SPSS 20.0 software program was used for statistical analysis.
Non-normally distributed quantitative data were presented as
median and quartile ranges [M(P25, P75)] and analyzed with the
Wilcoxon rank sum test for intergroup comparisons. Qualitative
data were described using relative numbers, and the χ2 test was
used for comparisons between these groups. Logistic regression
analysis was used for multivariate analysis. p < 0.05 was required
for differences to be considered statistically significant.
Note: a is described by median and quartile, and the statistic
was the Z-value; other items were described as numbers (n–
%), and the statistic was the χ2 value. b There was a negative
correlation between the value and significance.
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FIGURE 1 | (A) Among the 509 hospitalized patients, the most frequent infection agent was Candida parapsilosis (177/509, 34.8%), followed by Candida
guilliermondii (136/509, 26.7%), Candida albicans (94/509, 18.5%), Candida glabrata (41/509, 8.1%), Candida tropicalis (39/509, 7.7%), and Cryptococcus
neoformans (14/509, 2.8%), with low rates of incidence obtained for the remaining infections, which included those caused by Candida krusei (5/509), Candida
lusitaniae (2/509) and Candida streptococcus (1/509). (B) From 2013 to 2018, changes in the number of IFI patients. (C) Compared to other regions, we have a
different proportion of fungal species. (D) Compared to other regions, we have a lower IFI incidence.
RESULTS
General Information
A total of 509 hospitalized patients with IFI were included in
this study, with an average ± SD age of 60.1 ± 16.4 (range:
1–93 years old), among which almost 40% were ≥65 years
old (202/509, 39.7%), and most were male (322/509, 63.3%).
In this study, unlike in other studies, Candida albicans was
not the most frequently observed cause of infection in these
patients (Timsit et al., 2016; Ostrosky-Zeichner and Al-Obaidi,
2017). The most frequent infection agent in our sample was
Candida parapsilosis (177/509, 34.8%), followed by Candida
guilliermondii (136/509, 26.7%), Candida albicans (94/509,
18.5%), Candida glabrata (41/509, 8.1%), Candida tropicalis
(39/509, 7.7%), and Cryptococcus neoformans (14/509, 2.8%),
with low rates of incidence obtained for the remaining infections,
which included those caused by Candida krusei (5/509),
Candida lusitaniae (2/509) and Candida streptococcus (1/509)
(Figure 1A). All patients with IFI had at least one associated
condition, with the most common concomitant conditions being
recent surgery (within 2 weeks) (365/509, 71.7%), followed
by hypoproteinaemia (354/509, 69.5%), malignancy (197/509,
38.7%), diabetes (71/509, 13.9%), septic shock (69/509, 13.6%),
renal failure (57/509, 11.2%), and AIDS (8/509, 1.6%). In this
study, the most common risk factors associated with IFI were
prolonged hospitalization (489/509, 96.1%), total parenteral
nutrition (404/509, 79.4%), and the presence of catheters
(401/509, 78.8%). Supplementary Table 1 contains a summary
of the clinical characteristics and inducing factors of candidiasis
in the patients included in this study. From 2013 to 2018,
the number of IFIs per year was relatively stable (Figure 1B).
Compared with those in other regions within a similar time
frame, the fungal species observed in our patients showed a
different proportion (Figure 1C), and our infection rates were
very low (Figure 1D).
In vitro Antifungal Susceptibility Test
The sensitivity test results for the 486 isolates to the five
antifungal drugs are shown in Supplementary Table 2. Of
the isolates tested, 41/486 (8.4%) were resistant to at least
one antifungal agent. For fluconazole, 428/485 (88.2%) of the
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Candida strains were found to be susceptible. Isolates of Candida
glabrata showed the highest susceptibility-dose dependence
(SDD) to fluconazole (33/41, 80.5%), while the highest resistance
was observed with Candida krusei (4/5, 80%). It is important to
note that 6 isolates (3 Candida tropicalis, 2 Candida glabrata, and
1 Candida albicans) showed cross resistance between fluconazole
and voriconazole, 14 isolates (6 Candida glabrata, 4 Candida
guilliermondii, 3 Candida krusei, and 1 Candida albicans)
between fluconazole and itraconazole, 17 isolates (9 Candida
glabrata, 7 Candida tropicalis, and 1 Cryptococcus neoformans)
showed cross resistance between fluconazole, voriconazole, and
itraconazole. And 1 (Candida krusei) showed cross resistance
between fluconazole, itraconazole, and flucytosine. However, no
cross resistance was detected between azoles and amphotericin B.
Risk Factors for Candida albicans and
Non-Candida albicans Infection
The demographic and clinical characteristics of Candida
albicans- vs. non-Candida albicans-infected patients are listed
in Supplementary Table 3. Non-Candida albicans infection was
more often associated with tumors, central venous catheters,
drainage tubes and total parenteral nutrition than Candida
albicans infection. A larger proportion of Candida albicans
infection patients were admitted to the ICU, the duration of
their ICU stays was longer, they exhibited a greater incidence of
septic shock, and lower levels of neutrophils, lymphocytes, and
leukocyte were present in these patients.
Analysis of Risk Factors in Patients With
Persistent and Non-persistent Fungal
Infections
The demographic and clinical characteristics of patients with
persistent vs. non-persistent fungal infections are listed in
Supplementary Table 4. Patients with persistent infections were
more likely to have renal failure, invasive mechanical ventilation,
and multiple/prolonged ICU admissions. Patients with non-
persistent fungal infections more often had recent surgery
(within 2 weeks) and lower levels of neutrophils, lymphocytes,
leukocytes, and PCT.
Analysis of Risk Factors in Patients With
Isolated Fungal Infection and Multiple
Fungal Infections
The demographic and clinical characteristics of patients with
isolated fungal infections vs. multiple fungal infections are
listed in Supplementary Table 5. Patients with isolated fungal
infections were more likely to be male, possess tumors, have
a recent surgery (within 2 weeks) and have lower levels of
lymphocytes, PCT, and CRP. Patients with multiple fungal
infections were older; experienced longer lengths of stays and
multiple hospitalizations; were more likely to be admitted and
stayed longer in the ICU; were more likely to have diabetes, renal
failure, septic shock, and persistent fungal infections; and more
often used gastric tubes, central venous catheters, and invasive
mechanical ventilation.
Risk Factor Analysis of Patients With and
Without Bacteraemia
The demographic and clinical characteristics of patients with
vs. without bacteraemia are listed in Table 1. Patients with
bacteraemia were older; more often had diabetes, renal failure
and septic shock; used invasive mechanical ventilation, catheters,
stomach tubes, and central venous catheters; and had persistent
fungal infections, as well as multiple/prolonged ICU stays and
more frequent hospital admissions. Patients without bacteraemia
were more likely to have tumors, recent surgery (within 2 weeks)
and lower levels of neutrophils, lymphocytes, leukocytes, total
bilirubin, PCT, and CRP. These patients with IFI comprisedmore
than half of the patients with bacterial disease (246/453, 54.3%),
with Acinetobacter baumannii (111/246, 45.1%) being the most
common bacterial infection, followed by Enterococcus faecium
(72/246, 29.3%), Pseudomonas aeruginosa (65/246, 26.4%),
Escherichia coli (55/246, 22.4%), and Klebsiella pneumoniae
(46/246, 18.7%) (Figure 2). We cultured 28 species of 591
bacteria from 246 patients, of which 15 were Gram positive
(15/28, 53.6%) and 13 were Gram negative (13/28, 46.4%). The
specific data are presented in Supplementary Table 6. There
were 73 cases of single bacterial infection (73/246, 29.7%)
and 173 cases of multiple bacterial infection (173/246, 70.3%).
The specific data are presented in Supplementary Table 7. This
information provides the basis for the medication employed in
the early stage.
Analysis of Risk Factors for Survival and
Death in Patients
The demographic and clinical characteristics of survival vs.
mortality in patients are listed in Table 2. Patients who survived
were often those with tumors, total parenteral nutrition, drainage
tubes, recent surgery (within 2 weeks) and lower levels of
neutrophils, creatinine, leukocytes, total bilirubin, PCT, and
CRP. The patients who died were older, often with renal
failure, invasive mechanical ventilation, stomach tubes, central
venous catheters, septic shock, persistent fungal infection,
multiple/longer lengths of stays in the ICU, and more frequently
used immunosuppressants.
Prognostic Factors Associated With Death
In patients with invasive fungal infections, with death as the
dependent variable (0 = survival, 1 = death) in a univariate
analysis, statistically significant effects were obtained with regard
to age; length of hospital/ICU stay; levels of neutrophils,
creatinine, leukocytes, total bilirubin, PCT, and CRP; presence
of tumors; total parenteral nutrition; renal failure; recent
surgery; use of immunosuppressants within the past 30 days;
ICU admission; invasive mechanical ventilation; stomach tubes;
central venous catheters; drainage tubes; septic shock; multiple
hospitalizations; and persistent fungal infections as independent
variables with multivariate logistic regression analysis performed
by the conditional method. These results revealed that length of
ICU stay, renal failure, levels of neutrophils, and total bilirubin,
use of immunosuppressants within the past 30 days, ICU
admission, stomach tube placement, recent surgery, drainage
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TABLE 1 | Comparison of bacteremia patients vs. non-bacteremia patients.
Characteristic IFI patients without bacteremia (n = 207) IFI patients with bacteremia (n = 246) Statistic P-value
Gender (male) 125 (60.37%) 159 (64.63%) 0.867 0.352
Age (years)a 59.00 (50.75, 67.25) 63.00 (53.00, 74.25) −3.363 0.001
Length of stay (days)a 25.00 (20.00, 33.00) 45.50 (30.75, 75.50) −9.578 < 0.001
Length of stay in ICUa 0.00 (0.00, 2.00) 10.00 (0.00, 30.00) −10.550 < 0.001
Albumin (g/l)a 27.4 (23.6, 31.1) 27.3 (23.3, 31.0) −0.442 0.659
Neutrophils (109/L)a 4.85 (3.28, 7.73) 6.53 (4.38, 9.43) −4.503 < 0.001
Lymphocyte (109/L)a 0.61 (0.41, 0.89) 0.83 (0.55, 1.20) −4.813 < 0.001
Creatinine (g/l)a 59 (47, 75) 59 (41, 90) −0.023 0.981
Hemameba (109/L)a 5.98 (4.30, 9.44) 8.38 (5.77, 11.48) −5.063 < 0.001
Total bilirubin (umol/l)a 12.20 (7.10, 21.10) 15.10 (9.50, 28.73) −3.097 0.002
CRP (mg/l)a 39.80 (0.00, 96.10) 93.20 (28.30, 143.75) −5.726 < 0.001
PCT (ng/ml)a 0.24 (0.00, 0.71) 0.44 (0.16, 1.79) −4.516 < 0.001
Tumor 119 (57.49%) 96 (39.02%) 15.368 < 0.001
Diabetes 21 (10.14%) 47 (19.11%) 7.095 0.008
Pancreatitis 20 (9.66%) 25 (10.16%) 0.032 0.859
Total parenteral nutrition 166 (80.19%) 196 (79.67%) 0.019 0.891
Renal failure 15 (7.25%) 36 (14.63%) 6.141 0.013
Recent surgery (within 2 weeks) 136 (65.70%) 112 (45.53%) 18.463 < 0.001
Use immunosuppressants within the past 30 days 18 (8.70%) 15 (6.10%) 1.123 0.689
ICU 58 (28.02%) 168 (28.29%) 72.930 < 0.001
Hypoproteinemia 145 (70.05%) 169 (69.98%) 0.060 0.806
Invasive mechanical ventilation 42 (20.29%) 153 (62.20%) 80.517 < 0.001
Catheter 150 (72.46%) 210 (85.37%) 11.469 0.001
Stomach tube 101 (48.79%) 166 (67.48%) 16.221 < 0.001
Central venous catheter 104 (50.24%) 185 (75.20%) 30.326 < 0.001
Drainage tube 133 (64.25%) 168 (68.29%) 0.824 0.364
Septic shock 6 (2.90%) 58 (23.58%) 39.620 < 0.001
Multiple hospitalizations within 2 years (>2 times) 113 (54.59%) 167 (67.89%) 8.420 0.004
mortality 19 (9.18%) 85 (34.55%) 40.919 < 0.001
a is described by median and quartile, and the statistic was the Z-value; other items were described as numbers (n–%) and the statistic was the χ2-value.
tube placement, and septic shock were risk factors for death in
IFI patients (Table 3).
Comparison of Serum Marker Levels
Between Patients Who Survived and Those
Who Died
To assess the ability of serum markers to serve as prognostic
indicators for IFI, ROC analysis was performed using
significantly different immunological parameters between
patients who survived and those who did not. Serum PCT
(AUC 0.601, 95% CI 0.536–0.665, P = 0.003) possessed a
higher prognostic value in IFI patients than other parameters
(Figure 3A). The critical serum value for survival vs. death was
0.72 ng/ml, with a sensitivity of 57.0%, and a specificity of 61.9%.
Serum CRP (AUC 0.578, 95% CI 0.512–0.644, P = 0.020) was
also found to be valuable in predicting the prognosis of IFI
(Figure 3B). We also tested BDG within ROC analysis and found
that BDG (AUC 0.519, 95% CI 0.423–0.616, P = 0.693) failed to
be a significant factor for IFI prognosis (Table 4).
DISCUSSION
To better understand the clinical characteristics and prognostic
factors of IFI, we retrospectively surveyed 509 IFI patients with
different demographic and risk factors as well as clinical and
laboratory characteristics. It had been reported previously that
Candida albicans represents the most common invasive fungal
infection species (Fu et al., 2017), but our current data show
that the proportion of non-Candida albicans infections exceeds
that of Candida albicans infections, with Candida parapsilosis
being the most common Candida species. Such differences may
be attributable to the epidemiology of IFI, which can vary
depending on patient age, geographic area, medical practice and
antifungal use. According to our results, the overall incidence
of IFI in Northeast China (0.07/1,000) was substantially lower
than that reported in Italy (1.5/1,000), Israel (0.61/1,000), and
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FIGURE 2 | The bacterial and fungal species distribution of bacteremia complicated with IFI.
the United States (0.3/1,000) as well as in other regions within
China, such as Chongqing (0.32/1,000) and Beijing (0.55/1,000)
(Wang et al., 2014; Barchiesi et al., 2016; Eliakim-Raz et al.,
2016; Alothman et al., 2017). When assessing known potential
risk factors for IFI (Supplementary Table 1), we found that
the most common risk factor was prolonged hospitalization
(489/509, 96.1%), suggesting that IFI may be associated with
nosocomial infections resulting from prolonged hospitalization.
This observation is consistent with previous studies on fungal
infections (Pu et al., 2017). It seems likely that prolonged
hospitalizations may increase exposure to fungal pathogens,
which are abundant in hospital settings and difficult to eradicate
(Abreu et al., 2013). However, as long-term hospitalization is
often not an independent risk factor, it is important for the
clinician to consider and test for invasive fungal infections in
patients who have been hospitalized for longer than 10 days.
Other risk factors associated with IFI include total parenteral
nutrition (79.4%), catheters (78.8%), and recent surgery (71.7%)
(Supplementary Table 1). The common risk factors observed in
this study were similar to those reported by others (Zaoutis et al.,
2005; Wang et al., 2014; Barchiesi et al., 2016; Jia et al., 2018).
The main clinical features shown by the 509 IFI patients in
this study were an average age of 60.1 years, with almost 40%
being > 65 years old (202/509, 39.7%), a greater number of
males (322/509, 63.3%), and more who had continuously used
antibiotics for> 2 weeks (289/509, 56.8%). Overall, these findings
are similar to those of previous studies in China (Cheng et al.,
2005; Shigemura et al., 2014; Pu et al., 2017). In addition, we
observed that patients with hypoproteinaemia (354/509, 69.5%)
weremore likely to present IFI. Such patients may have weakened
immune function and/or other diseases, which would increase
their susceptibility to infection by fungal pathogens (Batzlaff and
Limper, 2017).
In our study, most IFI events occurred in the surgical ward
(331/509, 65.0%), but both the medical and surgical wards had
a significant number of patients who had been admitted to the
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 6 October 2020 | Volume 10 | Article 553648
Li et al. Review of Invasive Fungal Infection
TABLE 2 | Comparisons of patients that survived vs. died.
Characteristic Survival patients (n = 398) Death patients (n = 111) Statistic P-value
Gender (male) 244 (61.31%) 78 (70.27%) 3.001 0.083
Age (years)a 61.00 (51.50, 70.00) 64.00 (54.00, 78.00) −2.751 0.006
Length of stay (days)a 30.00 (23.00, 49.00) 42.00 (23.00, 75.00) −2.689 0.007
Length of stay in ICUa 0.00 (0.00, 7.00) 14.00 (1.00, 35.00) −8.233 < 0.001
Albumin(g/l)a 27.3 (23.5, 30.9) 27.5 (22.9, 32.3) −0.836 0.403
Neutrophils(109/L)a 5.55 (3.79, 8.25) 7.31 (4.35, 10.99) −3.065 0.002
Lymphocyte(109/L)a 0.73 (0.48, 1.08) 0.83 (0.55, 1.18) −1.529 0.126
Creatinine(g/l)a 56 (42, 74) 73 (56, 151) −3.658 < 0.001
Hemameba(109/L)a 7.15 (5.00, 10.17) 9.52 (6.12, 12,65) −3.174 0.002
Total bilirubin(umol/l)a 12.95 (7.50, 21.83) 18.60 (9.80, 35.70) −4.906 < 0.001
CRP(mg/l)a 56.75 (0.00, 104.25) 93.50 (30.80, 147.00) −4.906 < 0.001
PCT(ng/ml)a 0.23 (0.00, 0.75) 0.73 (0.24, 2.53) −5.701 < 0.001
Tumor 211 (53.01%) 33 (29.73%) 18.856 < 0.001
Diabetes 51 (12.81%) 20 (18.02%) 1.958 0.162
Pancreatitis 38 (9.55%) 11 (9.91%) 0.013 0.909
Total parenteral nutrition 329 (82.66%) 75 (67.57%) 12.080 0.001
Renal failure 32 (8.04%) 25 (22.52%) 18.306 < 0.001
Recent surgery (within 2 weeks) 241 (60.55%) 39 (35.14%) 22.657 < 0.001
Use immunosuppressants within the past 30 days 21 (5.28%) 13 (11.71%) 5.766 0.016
ICU 156 (39.20%) 82 (73.87%) 41.926 < 0.001
Hypoproteinemia 283 (71.11%) 71 (64.55%) 1.756 0.185
Invasive mechanical ventilation 132 (33.17%) 75 (65.77%) 38.347 < 0.001
Catheter 313 (78.64%) 88 (79.28%) 0.021 0.885
Stomach tube 213 (53.52%) 77 (69.37%) 8.897 0.003
Central venous catheter 233 (58.54%) 79 (71.17%) 5.834 0.016
Drainage tube 277 (69.60%) 58 (52.25%) 11.607 0.001
Septic shock 26 (6.53%) 42 (37.84%) 73.487 < 0.001
Multiple hospitalizations within 2 years (>2 times) 232 (58.29%) 78 (70.27%) 5.230 0.022
a is described by median and quartile, and the statistic was the Z-value; other items were described as numbers (n–%) and the statistic was the χ2-value.
TABLE 3 | Multivariate Logistic regression analysis of prognostic factors associated with death.
β Sx̄ Waldχ
2 P-value OR 95%CI
Length of stay in ICU 0.012 0.005 5.699 0.017 1.012 1.002∼1.002
Neutrophils 0.074 0.027 7.745 0.005 1.077 1.022–1.134
Total bilirubin 0.007 0.003 4.379 0.036 1.007 1.000–1.013
Renal failure 0.978 0.345 8.050 0.005 2.658 1.353∼5.223
Recent surgery (within 2 weeks) −1.022 0.318 10.355 0.001 0.360 0.193∼0.671
Use immunosuppressants within the past 30 days 1.267 0.437 8.404 0.004 3.549 1.507∼8.359
ICUa 0.802 0.347 5.338 0.021 2.230 1.129∼4.405
Stomach tube 0.753 0.352 4.568 0.033 2.123 1.064∼4.233
Drainage tube −0.970 0.329 8.720 0.003 0.379 0.199∼0.722
Septic shock 1.994 0.334 35.648 < 0.001 7.344 3.817∼14.131
athere was a negative correlation between the value and significance.
ICU during their hospitalization, suggesting that the basic state
of the patients was associated with IFI infection risk. A number
of factors may contribute to these differences, including the size
of the department, patient population and size of the hospital.
Thus, specific predictors of IFI may differ among hospitals, as
well as in different wards within the hospital. In our study,
the majority of surgical patients underwent abdominal surgery,
which may damage the gastrointestinal barrier. Such a procedure
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FIGURE 3 | Receiver operation characteristics (ROC) analysis of two independent mortality risk factors (A) PCT (B) CRP.
TABLE 4 | Receiver operating characteristics curve analysis of immune parameters predicting death.
AUC 95%CI P-value Optimal threshold value Sensitivity Specificity
BDG 0.519 (0.423–0.616) 0.693 10.88 78.0% 27.0%
PCT 0.601 (0.536–0.665) 0.003 0.72 57.0% 61.9%
CRP 0.578 (0.512–0.644) 0.020 111.50 48.5% 68.4%
CD4 0.517 (0.399–0.635) 0.780 154.50 76.9% 33.9%
CD8a 0.509 (0.389–0.629) 0.880 143.00 48.7% 64.3%
CD3a 0.500 (0.376–0.624) 0.997 309.00 43.6% 71.4%
CD4/CD8 0.535 (0.501–0.655) 0.568 0.96 41.0% 73.2%
athere was a negative correlation between the value and significance.
can lead to skin contamination at the site of vascular insertion,
making these patients more susceptible to IFI (Moreno Elola-
Olaso et al., 2012; Prieto et al., 2014). In addition, IFI patients
who had been admitted to the ICU during hospitalization had
significantly higher mortality rates than those in the surgical
ward. Several factors may influence such differences, including
patient age, severity of primary disease and presence of various
comorbidities (Timsit et al., 2016; Ostrosky-Zeichner and Al-
Obaidi, 2017). Therefore, infection control measures should be
individually designed and implemented for specific use within
each different ward to reduce the incidence of IFI. We also found
that resistance to azoles was observed mainly in C. tropicalis and
C. glabrata isolates, a result that was similar to that previously
reported (Wang et al., 2016). These findings have important
implications for the selection of empirical antifungal agents in
patients suspected of candidiasis.
To our knowledge, the findings presented here are the first to
report that more than half of these IFI patients had bacteraemia
(246/453, 54.3%), which should alert and introduce a cautionary
note to clinicians treating IFI patients. Acinetobacter baumannii
(111/246, 45.1%) was the most common co-infecting bacterium,
followed by Enterococcus faecalis (72/246, 29.3%), Pseudomonas
aeruginosa (65/246, 26.4%), Escherichia coli (55/246, 22.4%),
and Klebsiella pneumoniae (46/246, 18.7%). Of the 246 patients
with IFI concomitant with bacteraemia, 73 (29.7%) presented
with a single bacterial infection, and the remaining 173
(70.3%) presented with multiple bacterial infections. These rates
of bacterial infection provide a basis and guidance for the
treatment of bacterial infections in IFI patients. Fungi and
bacteria can produce both synergistic or antagonistic effects, and
Acinetobacter baumannii can use ethanol produced by yeast as a
carbon source to enhance its growth (Smith et al., 2004; Garsin
and Lorenz, 2013). Pseudomonas aeruginosa often synergizes
with fungi, with the result that Aspergillus fumigatus can enhance
elastase production in co-cultures with Pseudomonas aeruginosa,
leading to a poor prognosis in IFI patients (Smith et al., 2015;
Pekmezovic et al., 2016). Fungal 1,3-glucan has been shown
to increase the tolerance of Escherichia coli to ofloxacin in
Escherichia coli/Candida albicans biofilms (Tang et al., 2018). The
mortality rates of IFI patients with bacteraemia (85/246, 34.6%)
were significantly greater than those of patients without bacterial
infection (19/207, 9.2%), which is a noteworthy factor with
regard to the clinical treatment of IFI patients presenting with
this specific condition. Another clinical mortality complication
related to fungal infections was septic shock (13.6%). This
situation may be related to the individual patient’s condition
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 8 October 2020 | Volume 10 | Article 553648
Li et al. Review of Invasive Fungal Infection
along with a lack of timely antifungal treatment, leading to a poor
prognosis in these patients.
The results of our study also suggest that serum CRP and PCT
levels may be reliable predictors of mortality. These findings are
consistent with some recent studies and indicate the potential
of these markers for prognosis (Giacobbe et al., 2017; Tang
et al., 2018; Cortegiani et al., 2019). While the commonly used
diagnostic biomarker for IFI is an elevation in serum BDG
levels (León et al., 2012; Posteraro et al., 2016), in our study,
we found that elevated BDG was not a reliable indicator of
prognosis. Therefore, we suggest that serum PCT and CRP can
more effectively serve as predictors of survival and death in
these patients.
This study has some limitations. First, as it was conducted
in only one hospital; thus, it cannot be determined whether
these results can be extrapolated to IFI cases elsewhere. We
hope to expand upon this research at other sites. Second, as
the identified fungal species were confirmed using the fungal
culture method, the possibility of an error in the identification of
these fungi cannot be completely ruled out. Third, the severity of
patients was not graded prior to treatment, which may introduce
a confounding factor in the analysis of treatment outcomes.
Despite these limitations, this study represents the first
comprehensive description of pathogens, clinical characteristics,
and potential risk factors for mortality in IFI patients within this
region. Such information can provide new insights and protocols
for improvements in IFI management.
CONCLUSIONS
In this study, we identified clinical characteristics and risk factors
associated with mortality rates in patients with IFI, along with the
first review of epidemiological information on IFI patients with
bacteraemia. Candida parapsilosis was found to comprise the
main type of infection, followed by Candida guilliermondii and
Candida albicans. Risk factors, such as longer ICU stays, renal
insufficiency, immunosuppressive agents, levels of neutrophils
and total bilirubin, ICU admission rates, gastric tube placement,
and septic shock, were independently associated with mortality.
Serum PCT and CRP levels can serve as effective biomarkers for
the prognosis of IFI. These findings will greatly aid clinical health
care workers with regard to the identification, prevention and
treatment of IFI in hospitalized patients.
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